Nonalcoholic fatty liver disease. low free sugar diet, lipid profile, glycemic indices, liver enzymes, inflammatory factors, hepatic steatosis , fibrosis , patients with Nonalcoholic fatty liver disease
Conditions
Interventions
Intervention 1: Intervention group: a low free sugar diet with dietary and physical activity recommendations/12 weeks. Intervention 2: Control group: Dietary and physical activity recommendations/12 w
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: The desire to participate in research Age 60-18 years BMI above 20 Evidence of non-alcoholic steatohepatitis (inflammation and swelling of hepatocytes) second and third degree in ultrasonography Evidence of non-alcoholic steatohepatitis in fibro-scan results with CAP Score over 263 Lack of a history of alcohol consumption or alcohol consumption less than 10 grams per day in women and less than 20 grams per day in men Lack of other chronic and acute liver diseases and disorders (hepatitis B, C, etc.), biliary disease, autoimmune diseases, cancer and hereditary disorders affecting the condition of the liver (iron, copper storage disease) and cirrhosis Lack of pregnancy or lactation in women No consumption of hepatotoxic drugs such as phenytoin, tamoxifen and lithium, and drugs that affect liver function
Exclusion criteria
Exclusion criteria: Lack of desire to continue research Forced to use antibiotics or hepatotoxic drugs during the study Non-compliance with low free sugar diet
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatic steatosis, Liver fibrosis. Timepoint: At the first and at the 12th week of the study. Method of measurement: Fibroscan. | — |
Secondary
| Measure | Time frame |
|---|---|
| Weight. Timepoint: At the first , 6th and 12th week of the study. Method of measurement: Scale.;BMI. Timepoint: At the first , 6th and 12th week of the study. Method of measurement: Calculate.;Waist to hip ratio. Timepoint: At the first , 6th and 12th week of the study. Method of measurement: Calculate.;Liver enzymes (AST,ALT,GGT). Timepoint: At the first and at the 12th week of the study. Method of measurement: Enzymatic method.;Lipid profile (TG,Total cholesterol,LDL-C,HDL-C). Timepoint: At the first and at the 12th week of the study. Method of measurement: Enzymatic method.;FBS. Timepoint: At the first and at the 12th week of the study. Method of measurement: Enzymatic method.;Insulin. Timepoint: At the first and at the 12th week of the study. Method of measurement: Radioimmunoassay.;Hs-CRP. Timepoint: At the first and at the 12th week of the study. Method of measurement: ELISA.;TNF-a. Timepoint: At the first and at the 12th week of the study. Method of measurement: ELISA.;NF-?B. Timepoint: At the first and at the 12th week of the study. Method of measurement: ELISA.;HOMA-IR. Timepoint: At the first and at the 12th week of the study. Method of measurement: Calculate.;QUICKI. Timepoint: At the first and at the 12th week of the study. Method of measurement: Calculate. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactazita hekmatdoost
Shahid Beheshti University of Medical Sciences
Outcome results
None listed